Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double blind, placebo-controlled study to assess whether the administration of ramelteon could facilitate the discontinuation of zolpidem (Ambien) greater than or equal to 10 mg therapy in subjects with chronic insomnia.

Next Previous
X
Search
Trial Profile

Randomized, double blind, placebo-controlled study to assess whether the administration of ramelteon could facilitate the discontinuation of zolpidem (Ambien) greater than or equal to 10 mg therapy in subjects with chronic insomnia.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2013

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramelteon (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center

    • Most Recent Events

    • 30 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Planned number of patients changed from 130 to 135 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top